Where Does Phibro Animal Health Stock Rank Among Competitors?
Phibro Animal Health’s stock soared over the past year, far outperforming its animal health peers, but how does this smaller player truly measure up? A closer look reveals exceptional revenue growth compared to rivals. However, PAHC’s operating and free cash flow margins remain modest against industry leaders, despite a competitive PE valuation, balancing its rapid expansion with the established profitability of larger market players.
- PAHC’s 11.5% operating margin, trailing ZTS (37.6%), implies distinct cost structures or market positioning, possibly in less premium segments.
- PAHC’s 32.4% LTM revenue growth, outpacing ZTS, ELAN, MRK, NEOG, IDXX, signals robust demand for its specialized animal health solutions.
- PAHC’s 127.1% past year gain, outperforming peers, and 22.0 PE reflects strong investor confidence in its growth trajectory.
Here’s how Phibro Animal Health stacks up across size, valuation, and profitability versus key peers.
| PAHC | ZTS | ELAN | MRK | NEOG | IDXX | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 2.0 | 56.1 | 12.1 | 298.8 | 2.3 | 51.5 |
| Revenue ($ Bil) | 1.5 | 9.4 | 4.6 | 64.2 | 0.9 | 4.2 |
| PE Ratio | 22.0 | 21.2 | 335.5 | 15.7 | -3.8 | 50.2 |
| LTM Revenue Growth | 32.4% | 2.7% | 3.1% | 1.7% | -3.7% | 8.4% |
| LTM Operating Margin | 11.5% | 37.6% | 5.2% | 34.9% | -3.3% | 31.3% |
| LTM FCF Margin | 3.2% | 23.8% | 7.7% | 20.3% | -2.1% | 22.6% |
| 12M Market Return | 127.1% | -26.8% | 102.1% | 38.6% | -1.7% | 37.4% |
For more details on Phibro Animal Health, read Buy or Sell PAHC Stock. Below we compare PAHC’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
- Get Paid 9.0% to Buy ADSK at a 30% Discount – Here’s How
- The Smart Way to Own LLY: Collect 8.8% Before You Even Buy
- Cash Machine Trading Cheap – GoDaddy Stock Set to Run?
- Meta Platforms Stock Capital Return Hits $184 Bil
- Eli Lilly Stock Hands $51 Bil Back – Worth a Look?
- Alphabet Stock Hands $364 Bil Back – Worth a Look?
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| PAHC | 32.4% | 27.4% | 4.1% | 3.8% | |
| ZTS | 2.7% | – | 8.3% | 5.7% | 3.9% |
| ELAN | 3.1% | – | 0.5% | 0.1% | -7.4% |
| MRK | 1.7% | – | 6.7% | 1.4% | 21.7% |
| NEOG | -3.7% | -3.2% | 12.4% | 56.0% | |
| IDXX | 8.4% | – | 6.5% | 8.7% | 4.7% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| PAHC | 11.5% | 8.5% | 5.2% | 7.3% | |
| ZTS | 37.6% | – | 36.6% | 35.9% | 36.2% |
| ELAN | 5.2% | – | 5.7% | 7.4% | 8.7% |
| MRK | 34.9% | – | 31.5% | 4.9% | 30.8% |
| NEOG | -3.3% | -0.2% | 6.3% | 4.6% | |
| IDXX | 31.3% | – | 29.0% | 30.0% | 26.7% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| PAHC | 22.0 | 31.4 | 352.1 | 14.4 | |
| ZTS | 21.2 | – | 23.0 | 32.1 | 43.8 |
| ELAN | 335.5 | – | 33.1 | -4.8 | -93.3 |
| MRK | 15.7 | – | 15.6 | 691.5 | 19.0 |
| NEOG | -3.8 | -1.4 | -279.0 | -166.1 | |
| IDXX | 50.2 | – | 62.8 | 40.6 | 68.3 |
Still not sure about PAHC stock? Consider portfolio approach.
Stock Picking Falls Short Against Multi Asset Portfolios
Markets move differently but a mix of assets smooths volatility. A multi asset portfolio keeps you invested and reduces the impact of sharp drops in any single area.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices